Global Opioid-Induced Constipation (OIC) Treatment Market Size and Forecast to 2021
Opioid-Induced Constipation (OIC) Treatment Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom,Japan, South Korea and China).
In this report, the global Opioid-Induced Constipation (OIC) Treatment market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a CAGR of XX% during the period 2017 to 2021.
The report firstly introduced the Opioid-Induced Constipation (OIC) Treatment basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The major players profiled in this report include:
Takeda Pharmaceutical
Tongrentang
Pfizer
AIKO Biotechnology
GlaxoSmithKline
AstraZeneca
The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-
Naloxegol
Lubiprostone
Methylnaltrexone Bromide
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Opioid-Induced Constipation (OIC) Treatment for each application, including-
Constipation
Appliaction B
Appliaction C
In this report, the global Opioid-Induced Constipation (OIC) Treatment market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a CAGR of XX% during the period 2017 to 2021.
The report firstly introduced the Opioid-Induced Constipation (OIC) Treatment basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The major players profiled in this report include:
Takeda Pharmaceutical
Tongrentang
Pfizer
AIKO Biotechnology
GlaxoSmithKline
AstraZeneca
The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-
Naloxegol
Lubiprostone
Methylnaltrexone Bromide
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Opioid-Induced Constipation (OIC) Treatment for each application, including-
Constipation
Appliaction B
Appliaction C
PART I OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY OVERVIEW
CHAPTER ONE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY OVERVIEW
1.1 Opioid-Induced Constipation (OIC) Treatment Definition
1.2 Opioid-Induced Constipation (OIC) Treatment Classification and Product Type Analysis
Naloxegol
Lubiprostone
Methylnaltrexone Bromide
1.3 Opioid-Induced Constipation (OIC) Treatment Application and Down Stream Market Analysis
Constipation
Appliaction B
Appliaction C
1.4 Opioid-Induced Constipation (OIC) Treatment Industry Chain Structure Analysis
1.5 Opioid-Induced Constipation (OIC) Treatment Industry Development Overview
1.6 Opioid-Induced Constipation (OIC) Treatment Global Market Comparison Analysis
1.6.1 Opioid-Induced Constipation (OIC) Treatment Global Import Market Analysis
1.6.2 Opioid-Induced Constipation (OIC) Treatment Global Export Market Analysis
1.6.3 Opioid-Induced Constipation (OIC) Treatment Global Main Region Market Analysis
1.6.4 Opioid-Induced Constipation (OIC) Treatment Global Market Comparison Analysis
1.6.5 Opioid-Induced Constipation (OIC) Treatment Global Market Development Trend Analysis
PART II ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER TWO 2012-2017 ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
2.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
2.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
2.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
2.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
2.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
2.6 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER THREE ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT KEY MANUFACTURERS ANALYSIS
3.1 Takeda Pharmaceutical
3.1.1 Product Picture and Specification
3.1.2 Capacity Production Price Cost Production Value Analysis
3.1.3 Contact Information
3.2 Tongrentang
3.2.1 Product Picture and Specification
3.2.2 Capacity Production Price Cost Production Value Analysis
3.2.3 Contact Information
3.3 Company C
3.3.1 Product Picture and Specification
3.3.2 Capacity Production Price Cost Production Value Analysis
3.3.3 Contact Information
CHAPTER FOUR ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
4.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
4.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
4.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
4.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
4.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
4.6 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
PART III NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER FIVE 2012-2017 NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
5.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
5.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
5.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
5.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
5.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
5.6 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER SIX NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT KEY MANUFACTURERS ANALYSIS
6.1 Pfizer
6.1.1 Product Picture and Specification
6.1.2 Capacity Production Price Cost Production Value Analysis
6.1.3 Contact Information
6.2 AIKO Biotechnology
6.2.1 Product Picture and Specification
6.2.2 Capacity Production Price Cost Production Value Analysis
6.2.3 Contact Information
CHAPTER SEVEN NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
7.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
7.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
7.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
7.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
7.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
7.6 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
PART IV EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY ANALYSIS (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER EIGHT 2012-2017 EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
8.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
8.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
8.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
8.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
8.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
8.6 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER NINE EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT KEY MANUFACTURERS ANALYSIS
9.1 GlaxoSmithKline
9.1.1 Product Picture and Specification
9.1.2 Capacity Production Price Cost Production Value Analysis
9.1.3 Contact Information
9.2 AstraZeneca
9.2.1 Product Picture and Specification
9.2.2 Capacity Production Price Cost Production Value Analysis
9.2.3 Contact Information
CHAPTER TEN EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
10.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
10.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
10.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
10.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
10.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
10.6 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
PART V OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT MARKETING CHANNELS AND INVESTMENT FEASIBILITY
CHAPTER ELEVEN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT MARKETING CHANNELS DEVELOPMENT PROPOSALS ANALYSIS
11.1 Opioid-Induced Constipation (OIC) Treatment Marketing Channels Status
11.2 Opioid-Induced Constipation (OIC) Treatment Marketing Channels Characteristic
11.3 Opioid-Induced Constipation (OIC) Treatment Marketing Channels Development Trend
11.2 New Firms Enter Market Strategy
11.3 New Project Investment Proposals
CHAPTER TWELVE DEVELOPMENT ENVIRONMENTAL ANALYSIS
12.1 China Macroeconomic Environment Analysis
12.2 European Economic Environmental Analysis
12.3 United States Economic Environmental Analysis
12.4 Japan Economic Environmental Analysis
12.5 Global Economic Environmental Analysis
CHAPTER THIRTEEN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS
13.1 Opioid-Induced Constipation (OIC) Treatment Market Analysis
13.2 Opioid-Induced Constipation (OIC) Treatment Project SWOT Analysis
13.3 Opioid-Induced Constipation (OIC) Treatment New Project Investment Feasibility Analysis
PART VI GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY CONCLUSIONS
CHAPTER FOURTEEN 2012-2017 GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
14.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
14.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
14.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
14.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
14.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER FIFTEEN GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
15.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
15.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
15.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
15.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
15.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER SIXTEEN GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY RESEARCH CONCLUSIONS
CHAPTER ONE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY OVERVIEW
1.1 Opioid-Induced Constipation (OIC) Treatment Definition
1.2 Opioid-Induced Constipation (OIC) Treatment Classification and Product Type Analysis
Naloxegol
Lubiprostone
Methylnaltrexone Bromide
1.3 Opioid-Induced Constipation (OIC) Treatment Application and Down Stream Market Analysis
Constipation
Appliaction B
Appliaction C
1.4 Opioid-Induced Constipation (OIC) Treatment Industry Chain Structure Analysis
1.5 Opioid-Induced Constipation (OIC) Treatment Industry Development Overview
1.6 Opioid-Induced Constipation (OIC) Treatment Global Market Comparison Analysis
1.6.1 Opioid-Induced Constipation (OIC) Treatment Global Import Market Analysis
1.6.2 Opioid-Induced Constipation (OIC) Treatment Global Export Market Analysis
1.6.3 Opioid-Induced Constipation (OIC) Treatment Global Main Region Market Analysis
1.6.4 Opioid-Induced Constipation (OIC) Treatment Global Market Comparison Analysis
1.6.5 Opioid-Induced Constipation (OIC) Treatment Global Market Development Trend Analysis
PART II ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER TWO 2012-2017 ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
2.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
2.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
2.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
2.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
2.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
2.6 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER THREE ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT KEY MANUFACTURERS ANALYSIS
3.1 Takeda Pharmaceutical
3.1.1 Product Picture and Specification
3.1.2 Capacity Production Price Cost Production Value Analysis
3.1.3 Contact Information
3.2 Tongrentang
3.2.1 Product Picture and Specification
3.2.2 Capacity Production Price Cost Production Value Analysis
3.2.3 Contact Information
3.3 Company C
3.3.1 Product Picture and Specification
3.3.2 Capacity Production Price Cost Production Value Analysis
3.3.3 Contact Information
CHAPTER FOUR ASIA OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
4.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
4.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
4.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
4.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
4.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
4.6 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
PART III NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER FIVE 2012-2017 NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
5.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
5.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
5.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
5.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
5.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
5.6 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER SIX NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT KEY MANUFACTURERS ANALYSIS
6.1 Pfizer
6.1.1 Product Picture and Specification
6.1.2 Capacity Production Price Cost Production Value Analysis
6.1.3 Contact Information
6.2 AIKO Biotechnology
6.2.1 Product Picture and Specification
6.2.2 Capacity Production Price Cost Production Value Analysis
6.2.3 Contact Information
CHAPTER SEVEN NORTH AMERICAN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
7.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
7.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
7.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
7.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
7.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
7.6 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
PART IV EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY ANALYSIS (THE REPORT COMPANY INCLUDING THE BELOW LISTED BUT NOT ALL)
CHAPTER EIGHT 2012-2017 EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
8.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
8.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
8.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
8.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
8.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
8.6 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER NINE EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT KEY MANUFACTURERS ANALYSIS
9.1 GlaxoSmithKline
9.1.1 Product Picture and Specification
9.1.2 Capacity Production Price Cost Production Value Analysis
9.1.3 Contact Information
9.2 AstraZeneca
9.2.1 Product Picture and Specification
9.2.2 Capacity Production Price Cost Production Value Analysis
9.2.3 Contact Information
CHAPTER TEN EUROPE OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
10.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
10.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
10.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
10.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
10.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Import Export Consumption Analysis
10.6 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
PART V OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT MARKETING CHANNELS AND INVESTMENT FEASIBILITY
CHAPTER ELEVEN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT MARKETING CHANNELS DEVELOPMENT PROPOSALS ANALYSIS
11.1 Opioid-Induced Constipation (OIC) Treatment Marketing Channels Status
11.2 Opioid-Induced Constipation (OIC) Treatment Marketing Channels Characteristic
11.3 Opioid-Induced Constipation (OIC) Treatment Marketing Channels Development Trend
11.2 New Firms Enter Market Strategy
11.3 New Project Investment Proposals
CHAPTER TWELVE DEVELOPMENT ENVIRONMENTAL ANALYSIS
12.1 China Macroeconomic Environment Analysis
12.2 European Economic Environmental Analysis
12.3 United States Economic Environmental Analysis
12.4 Japan Economic Environmental Analysis
12.5 Global Economic Environmental Analysis
CHAPTER THIRTEEN OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT NEW PROJECT INVESTMENT FEASIBILITY ANALYSIS
13.1 Opioid-Induced Constipation (OIC) Treatment Market Analysis
13.2 Opioid-Induced Constipation (OIC) Treatment Project SWOT Analysis
13.3 Opioid-Induced Constipation (OIC) Treatment New Project Investment Feasibility Analysis
PART VI GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY CONCLUSIONS
CHAPTER FOURTEEN 2012-2017 GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT PRODUCTIONS SUPPLY SALES DEMAND MARKET STATUS AND FORECAST
14.1 2012-2017 Opioid-Induced Constipation (OIC) Treatment Capacity Production Overview
14.2 2012-2017 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
14.3 2012-2017 Opioid-Induced Constipation (OIC) Treatment Demand Overview
14.4 2012-2017 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
14.5 2012-2017 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER FIFTEEN GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY DEVELOPMENT TREND
15.1 2017-2021 Opioid-Induced Constipation (OIC) Treatment Capacity Production Trend
15.2 2017-2021 Opioid-Induced Constipation (OIC) Treatment Production Market Share Analysis
15.3 2017-2021 Opioid-Induced Constipation (OIC) Treatment Demand Trend
15.4 2017-2021 Opioid-Induced Constipation (OIC) Treatment Supply Demand and Shortage Analysis
15.5 2017-2021 Opioid-Induced Constipation (OIC) Treatment Cost Price Production Value Profit Analysis
CHAPTER SIXTEEN GLOBAL OPIOID-INDUCED CONSTIPATION (OIC) TREATMENT INDUSTRY RESEARCH CONCLUSIONS
